Ustekinumab is a monoclonal antibody against the p40 subunit of IL-12 IL-23 interleukins and inhibits the actions of these cytokines, which are involved in the pathogenesis of psoriasis and other inflammatory conditions. Here, IL37 is linked to psoriasis.